If you have been reading about half-life and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
==== Lymphatic system ==== The circulatory system processes an average of 20 litres of blood per day through capillary filtration, which removes plasma from the blood. Roughly 17 litres of the filtered blood are reabsorbed directly into the blood vessels. The lymphatic system provides an accessory return route to the blood for the remaining three litres of interstitial fluid.
==== United Nations ==== While engaged in scheduling debates in the United States, the DEA also pushed for international scheduling. In 1985, the World Health Organization's Expert Committee on Drug Dependence recommended that MDMA be placed in Schedule I of the 1971 United Nations Convention on Psychotropic Substances. The committee made this recommendation on the basis of the pharmacological similarity of MDMA to previously scheduled drugs, reports of illicit trafficking in Canada, drug seizures in the United States, and lack of well-defined therapeutic use. While intrigued by reports of psychotherapeutic uses for the drug, the committee viewed the studies as lacking appropriate methodological design and encouraged further research. Committee chairman Paul Grof dissented, believing international control was not warranted at the time and a recommendation should await further therapeutic data. The Commission on Narcotic Drugs added MDMA to Schedule I of the convention on 11 February 1986.
=== In English translation === Kermani, Navid (2011). The Terror of God: Attar, Job and the Metaphysical Revolt. Translated by Wieland Hoban. Cambridge, UK: Polity. ISBN 978-0-7456-4527-8. OCLC 668946700. Kermani, Navid (2015). God is Beautiful: The Aesthetic Experience of the Quran. Translated by Tony Crawford. Cambridge, UK: Polity Press. ISBN 978-0745651675. OCLC 881418248. Kermani, Navid (2016). Between Quran and Kafka: West-eastern Affinities. Translated by Tony Crawford. Cambridge, UK: Polity Press. ISBN 978-1-5095-0033-8. OCLC 940342167. Kermani, Navid (2017). Upheaval: The Refugee Trek through Europe. Translated by Tony Crawford. Cambridge, UK: Polity Press. ISBN 978-1-5095-1868-5. OCLC 982184554. Kermani, Navid (2017). Wonder Beyond Belief: On Christianity. Translated by Tony Crawford (English ed.). Cambridge, UK: Polity Press. ISBN 978-1509514847. (2018 Schlegel-Tieck Prize.) Kermani, Navid (2018). State of Emergency: Travels in a Troubled World. Translated by Tony Crawford. Cambridge, UK: Polity. ISBN 978-1-5095-1470-0. Kermani, Navid (2019). Love Writ Large. Translated by Alexander Booth. London: Seagull Books. ISBN 978-0-85742-602-4. OCLC 1051682987. Kermani, Navid (2020). Along the Trenches: A Journey through Eastern Europe to Isfahan. Translated by Tony Crawford. Cambridge, UK: Polity Press. ISBN 978-1-5095-3557-6. OCLC 1097364913. Kermani, Navid (2022). Tomorrow Is Here: Speeches. Translated by Tony Crawford. Cambridge, UK: Polity Press. ISBN 978-1-5095-5056-2. OCLC 1292971292. Kermani, Navid (2023).
Sources: en.wikipedia.org
=== Wet === Wet or canned dog food usually is packaged in a solid or soft-sided container. Wet food contains roughly 60–78% water, which is significantly higher in moisture than dry or semi-moist food. Canned food is commercially sterile (cooked during canning); other wet foods may not be sterile. Sterilizing is done through the process of retorting, which involves steam sterilization at 121 degrees Celsius. A given wet food will often be higher in protein or fat compared to a similar dry food on a dry matter basis (a measure which ignores moisture); given the canned food's high moisture content. A larger amount of canned food must be fed in order to meet the dog's required needs. Grain gluten and other protein gels may be used in wet dog food to create artificial meaty chunks, which look like real meat. This food is usually used for old dogs or puppies.
Radio-controlled models – a popular hobby is playing with radio-controlled model boats, cars, airplanes, and helicopters (quadcopters) which are controlled by radio signals from a handheld console with a joystick. Most recent transmitters use the 2.4 GHz ISM band with multiple control channels modulated with PWM, PCM or FSK. Wireless doorbell – A residential doorbell that uses wireless technology to eliminate the need to run wires through the building walls. It consists of a doorbell button beside the door containing a small battery powered transmitter. When the doorbell is pressed it sends a signal to a receiver inside the house with a speaker that sounds chimes to indicate someone is at the door. They usually use the 2.4 GHz ISM band. The frequency channel used can usually be changed by the owner in case another nearby doorbell is using the same channel.
== Delivery vehicles == There are different types of drug delivery vehicles, such as polymeric micelles, liposomes, lipoprotein-based drug carriers, nano-particle drug carriers, dendrimers, etc. An ideal drug delivery vehicle must be non-toxic, biocompatible, non-immunogenic, biodegradable, and must avoid recognition by the host's defense mechanisms[3].
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.